ROS Generative Black Phosphorus-Tamoxifen Nanosheets for Targeted Endocrine-Sonodynamic Synergistic Breast Cancer Therapy
Jing Wang,Weijian Chen,Wenxiang Du,Hongjie Zhang,Matthias Ilmer,Lei Song,Yuan Hu,Xiaopeng Ma
DOI: https://doi.org/10.2147/ijn.s406627
IF: 7.033
2023-05-09
International Journal of Nanomedicine
Abstract:Jing Wang, 1, &ast Weijian Chen, 1, 2, &ast Wenxiang Du, 2 Hongjie Zhang, 2 Matthias Ilmer, 3 Lei Song, 2 Yuan Hu, 2 Xiaopeng Ma 1 1 Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, People's Republic of China; 2 State Key Laboratory of Fire Science, University of Science and Technology of China, Hefei, Anhui, 230026, People's Republic of China; 3 Department of General, Visceral, and Transplantation Surgery, Ludwig-Maximilians-University (LMU), Campus Grosshadern, Munich, 81377, Germany &astThese authors contributed equally to this work Correspondence: Yuan Hu; Xiaopeng Ma, Email ; Introduction: Tamoxifen (TAM) has proven to be a therapeutic breakthrough to reduce mortality and recurrence in estrogen receptor-positive (ER+) breast cancer patients. However, the application of TAM exhibits low bioavailability, off-target toxicity, instinct and acquired TAM resistance. Methods: We utilized black phosphorus (BP) as a drug carrier and sonosensitizer, integrated with TAM and tumor-targeting ligand folic acid (FA) to construct for synergistic endocrine and sonodynamic therapy (SDT) of breast cancer. The exfoliated BP nanosheets were modified through in situ polymerization of dopamine, followed by electrostatic adsorption of TAM and FA. The anticancer effect of was evaluated through in vitro cytotoxicity and in vivo antitumor model. RNA-sequencing (RNA-seq), quantitative real-time PCR, Western blot analysis, flow cytometry analysis and peripheral blood mononuclear cells (PBMCs) analysis were performed for mechanism investigation. Results: had satisfactory drug loading capacity, the TAM release behavior can be controlled through pH microenvironment and ultrasonic stimulation. An amount of hydroxyl radical (∙OH) and singlet oxygen ( 1 O 2 ) were as expected generated under ultrasound stimulation. nanoplatform showed excellent internalization in both TAM-sensitive MCF7 and TAM-resistant (TMR) cells. Using TMR cells, displayed significantly enhanced antitumor ability in comparison with TAM (7.7% vs 69.6% viability at 5μg/mL), the additional SDT further caused 15% more cell death. RNA-seq unraveled the antitumor mechanisms including effects on cell cycle, apoptosis and cell proliferation. Further analysis showed additional SDT successfully triggering reactive oxygen species (ROS) generation and mitochondrial membrane potential (MMP) reduction. Moreover, PBMCs exposed to induced an antitumor immune response by natural killer (NK) cell upregulation and immunosuppression macrophage reduction. Conclusion: The novel BP-based strategy not only delivers TAM specifically to tumor cells but also exhibits satisfactory antitumor effects through targeted therapy, SDT, and immune cell modulation. The nanoplatform may provide a superior synergistic strategy for breast cancer therapy. Keywords: black phosphorus, breast cancer, sonodynamic therapy, tamoxifen, PBMC, combination therapy Breast cancer is the most common cancer in women and accounts for 30% of all newly diagnosed cancers. 1 Approximately 70% of breast cancers are classified as estrogen receptor (ER+); 2 therefore, endocrine/hormonal target therapies that block endogenous estrogen have shown to reduce the risks of recurrence and death in breast cancer patients. The first clinical endocrine therapy, tamoxifen (TAM), which competes with estrogen to block estrogen signaling pathway, is considered as the standard first-line endocrine therapy, particularly in premenopausal women. 3,4 However, oral TAM therapy faces problems including poor bioavailability and rapid clearance. What is more, long-term administration exerts undesirable toxicity and carcinogenic effects, 5 including a risk of developing venous thromboembolism 6 and secondary cancers, 7,8 injuries to the central nervous system, 9 negative impacts on bone growth. Moreover, approximately 20–30% of patients eventually acquire resistance during or after treatment, 10 which cause a major hurdle for TAM clinical benefits. Therefore, it is essential to improve TAM therapeutic applications by strategies including increasing target specificity, improving therapeutic pharmacokinetics and reducing dose-dependent toxicity. Nanomaterials have been applied in the field of cancer research by providing strategies to achieve desired drug accumulation in tumors and minimize side effects on normal cells. Black phosphorus (BP) has demonstrated great potential in b -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology